Heart Failure
Conditions
Interventions
dapagliflozin group:Patients received dapaglifozin 10 mg once daily for 1year
Placebo group:Patients received placebo once daily for 1 year
Sponsors
Jiangxi Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: be at least 18 years old, have a confirmed diagnosis of type 2 diabetes, have an ejection fraction of 40% or lower, and exhibit New York Heart Association (NYHA) class II, III, or IV symptoms. Additionally, Patients were mandated to possess a plasma concentration of N-terminal pro-B-type natriuretic peptide (NT-proBNP) equal to or exceeding 600 pg per milliliter. If patients had atrial fibrillation or atrial flutter upon baseline electrocardiography, their NT-proBNP level needed to be at least 900 pg per milliliter.
Exclusion criteria
Exclusion criteria: recent use of or intolerable side effects related to an SGLT2 inhibitor, presence of type 1 diabetes mellitus, hypotension symptoms or a systolic blood pressure below 90 mm Hg, and an estimated glomerular filtration rate (eGFR) lower than 30 ml per minute per 1.73 m2 of body surface area (or experiencing rapid decline in renal function).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| left ventricular ejection fraction;left ventricular end-diastolic volume;left ventricular end-systolic volume;left ventricular end-diastolic diameter;left ventricular end-systolic diameter; | — |
Secondary
| Measure | Time frame |
|---|---|
| velocity time integral;Cardiac index output;Systolic pulmonary pressure; | — |
Countries
China
Contacts
Public ContactLan Cheng
Jiangxi Provincial People's Hospital
Outcome results
None listed